TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile Sells 7,157 Shares of Stock

TransMedics Group, Inc. (NASDAQ:TMDX) Director Edward M. Basile sold 7,157 shares of the business’s stock in a transaction on Tuesday, May 7th. The stock was sold at an average price of $129.98, for a total value of $930,266.86. Following the completion of the sale, the director now directly owns 1,193 shares in the company, valued at $155,066.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

TransMedics Group Stock Performance

TMDX stock opened at $127.22 on Thursday. The company has a market cap of $4.19 billion, a P/E ratio of -374.18 and a beta of 1.87. The company has a debt-to-equity ratio of 3.18, a current ratio of 9.72 and a quick ratio of 8.76. TransMedics Group, Inc. has a 1 year low of $36.42 and a 1 year high of $132.96. The stock’s fifty day moving average price is $88.31 and its 200-day moving average price is $78.91.

TransMedics Group (NASDAQ:TMDX) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.08) EPS. On average, equities analysts forecast that TransMedics Group, Inc. will post 0.62 earnings per share for the current year.

Hedge Funds Weigh In On TransMedics Group

A number of institutional investors have recently bought and sold shares of TMDX. State Board of Administration of Florida Retirement System lifted its holdings in TransMedics Group by 8.6% during the first quarter. State Board of Administration of Florida Retirement System now owns 9,843 shares of the company’s stock valued at $745,000 after purchasing an additional 780 shares in the last quarter. Entropy Technologies LP purchased a new position in shares of TransMedics Group in the first quarter valued at $201,000. ProShare Advisors LLC increased its position in TransMedics Group by 7.8% in the first quarter. ProShare Advisors LLC now owns 5,871 shares of the company’s stock worth $434,000 after purchasing an additional 427 shares during the last quarter. Russell Investments Group Ltd. raised its stake in TransMedics Group by 337,462.5% during the first quarter. Russell Investments Group Ltd. now owns 27,005 shares of the company’s stock valued at $1,997,000 after purchasing an additional 26,997 shares in the last quarter. Finally, Oppenheimer & Co. Inc. lifted its position in TransMedics Group by 156.6% during the first quarter. Oppenheimer & Co. Inc. now owns 26,570 shares of the company’s stock valued at $1,965,000 after purchasing an additional 16,214 shares during the last quarter. 99.67% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on TMDX shares. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research note on Wednesday, May 1st. Morgan Stanley increased their price target on shares of TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a report on Wednesday, February 28th. TD Cowen boosted their price objective on shares of TransMedics Group from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. JPMorgan Chase & Co. increased their target price on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a research note on Wednesday, May 1st. Finally, Oppenheimer upped their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a report on Wednesday, May 1st. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $119.00.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.